STR-P004
PreclinicalSmall molecule
STR-P004 is one of 37 small molecule programs targeting Kidney Disease. It is currently in Preclinical.
1
Indications
4
Total Trials
4
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
245 competitors in Kidney Disease
#DrugCompanyPhaseTrials
1Edarbi
TakedaPhase 3
Zemplar
AbbViePhase 3
Evrenzo
AstellasPhase 3
Invirase
RochePhase 3
Victoza
Novo NordiskPhase 3
Reata
BiogenPhase 3
Rituxan
RochePhase 3
Myfortic
NovartisPhase 3
Aranesp
AmgenPhase 3
Gazyva
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Kidney Disease1 trial
Unspecified1 trial
Exploratory Clinical Study on the Safety of STR-P004
Recruiting·—·N/A·NCT07143617·39 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for STR-P004. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SStarna Therapeutics